Alternative names:
SARS-CoV-2 Omicron variant

Specifications for
PepTivator
®
SARS-CoV-2 Prot_S B.1.1.529

Overview

PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator
®
SARS-CoV-2 Prot_S B.1.1.529 Mutation Pool covers selectively the mutated regions in the surface or spike glycoprotein (“S”) of the SARS-CoV-2 B.1.1.529 lineage (Omicron variant). PepTivator SARS-CoV-2 Prot_S B.1.1.529 WT Reference Pool covers the homologous domains of the Wuhan sequence.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Alternative names

SARS-CoV-2 Omicron variant

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first detected in December 2019 in Wuhan, China. Since that time the virus kept mutating, leading to new virus variants. The B.1.1.529 lineage, also known as Omicron variant, is a SARS-CoV-2 variant that was first discovered in South Africa and Botswana in November 2021. The mutations of this variant affect also immune relevant parts of structural SARS-CoV-2 proteins and the respective sequences are available in GISAID, a genome data base. The mutations listed below are taken from EPI_ISL_6704874. The B.1.1.529 lineage (Omicron variant) appears to be more infectious than other variants and was classified by the WHO as “variant of concern” in November 2021.
In total there are 37 mutations in the surface or spike glycoprotein (“S”) of the B.1.1.529 lineage (Omicron variant) compared to the Wuhan variant (reference genome GenBank MN908947.3): A67V, H69 deletion, V70 deletion, T95I, G142D, V143 deletion, Y144 deletion, Y145 deletion, N211 deletion, L212I, insertion 214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
The PepTivator
®
SARS-CoV-2 Prot_S B.1.1.529 Mutation Pool covers selectively the mutated regions. It consists of 83 peptides of 15 aa length. The PepTivator® SARS-CoV-2 Prot_S B.1.1.529 Mutation Pool can be used to supplement PepTivators covering the sequence of the wild-type spike glycoprotein (“S”) in order to detect immune responses towards both variants, Wuhan (wildtype) variant and B.1.1.529 lineage (Omicron variant). PepTivator Peptide pools spanning the sequence of the spike glycoprotein (“S”) of the Wuhan (wild-type) variant are PepTivator SARS-CoV-2 Prot_S (predicted immunodominant sequence domains), Prot_S1 (N-terminal S1 domain), Prot_S+ (part of the C-terminal S2 domain) and Prot_S Complete (all functional domains).
For control purposes, a respective wild-type (WT) reference pool covering the homologous domains of the Wuhan sequence is available. Comparison of the T cell immune response upon stimulation with mutation or reference pool can be used to analyze mutation-specific T cell responses. The PepTivator SARS-CoV-2 Prot_S B.1.1.529 WT Reference Pool covers the homologous domains of the Wuhan variant: A67, H69, V70, T95, G142, V143, Y144, Y145, N211, L212, (214 w/o insertion), G339, S371, S373, S375, K417, N440, G446, S477, T478, E484, Q493, G496, Q498, N501, Y505, T547, D614, H655, N679, P681, N764, D796, N856, Q954, N969, L981 (reference genome GenBank MN908947.3). PepTivator SARS-CoV-2 Prot_S B.1.1.529 WT Reference Pool serves as a control for the SARS-CoV-2 Prot_S B.1.1.529 Mutation Pool. Comparison of the T cell immune response upon stimulation with mutation and reference pool can be used to analyze mutation-specific T cell responses.

Applications

The
in vitro
stimulation of SARS-CoV-2–specific CD4
+
and CD8
+
T cells with PepTivators causes secretion of effector cytokines and upregulation of activation markers, which then allow the detection and isolation of SARS-CoV-2–specific T cells:
  • Detection and analysis of antigen-specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable antigen-specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation antigen-specific CD4+ and CD8+ effector/ memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells, e.g., for research on dendritic cell vaccination.

Related products for
PepTivator
®
SARS-CoV-2 Prot_S B.1.1.529

10 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?